Clinical Trial Update: Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS [Phase 3]

View source ↗

Summary

Phase 3 trial assessing safety and efficacy of AVP-923 for pseudobulbar affect in patients with ALS or MS; results were posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyotrophic Lateral Sclerosis
• Multiple Sclerosis
• Pseudobulbar Affect

Drugs mentioned

• AVP-923 (dextromethorphan/quinidine) (dextromethorphan/quinidine)

Snippet

Sponsor: Avanir Pharmaceuticals | Conditions: Pseudobulbar Affect (PBA) | Phase 3 | Status: COMPLETED | Results posted: 2013-07-10